CERo Other Current Liab from 2010 to 2024

CEROW Stock   0.01  0  14.29%   
CERo Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 56.7 K in 2024. During the period from 2010 to 2024, CERo Therapeutics Other Current Liabilities regression line of quarterly data had mean square error of 54.7 T and geometric mean of  117,718. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
59.7 K
Current Value
56.7 K
Quarterly Volatility
7.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CERo Therapeutics Correlation against competitors.

Latest CERo Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of CERo Therapeutics Holdings over the last few years. It is CERo Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

CERo Other Current Liab Regression Statistics

Arithmetic Mean2,015,206
Geometric Mean117,718
Coefficient Of Variation371.92
Mean Deviation3,612,372
Median83,639
Standard Deviation7,495,000
Sample Variance56.2T
Range29.1M
R-Value0.31
Mean Square Error54.7T
R-Squared0.1
Significance0.26
Slope517,106
Total Sum of Squares786.5T

CERo Other Current Liab History

202456.7 K
202359.7 K
202229.1 M

About CERo Therapeutics Financial Statements

CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities59.7 K56.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.